3 hours Iovance Biotherapeutics (NASDAQ:IOVA) Research Coverage Started at UBS GroupMarketBeat
UBS Group initiated coverage on Iovance Biotherapeutics in a report on Thursday. They set a “buy” rating and a $17.00 target price on the stock.
XUBS Group initiated coverage on Iovance Biotherapeutics in a report on Thursday. They set a “buy” rating and a $17.00 target price on the stock.
X